MedPath

MORPHINE SULFATE

These highlights do not include all the information needed to use MORPHINE SULFATE TABLETS safely and effectively. See full prescribing information for MORPHINE SULFATE TABLETS. MORPHINE SULFATE tablets, for oral use CII  Initial U.S. Approval: 1941

Approved
Approval ID

07593aa4-f2c4-4d6e-b186-ab2a4ecaa38a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 7, 2022

Manufacturers
FDA

Ascend Laboratories, LLC

DUNS: 141250469

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

MORPHINE SULFATE

PRODUCT DETAILS

NDC Product Code67877-670
Application NumberANDA212451
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateAugust 18, 2021
Generic NameMORPHINE SULFATE

INGREDIENTS (6)

MORPHINE SULFATEActive
Quantity: 15 mg in 1 1
Code: X3P646A2J0
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

MORPHINE SULFATE

PRODUCT DETAILS

NDC Product Code67877-671
Application NumberANDA212451
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateAugust 18, 2021
Generic NameMORPHINE SULFATE

INGREDIENTS (6)

MORPHINE SULFATEActive
Quantity: 30 mg in 1 1
Code: X3P646A2J0
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MORPHINE SULFATE - FDA Drug Approval Details